Study Title: Anticancer potential of (−)-epicatechin in a triple-negative mammary gland model
Citation: Almaguer et al., 2021 · Journal of Pharmacy and Pharmacology
What the Study Found: This study evaluated (-)-epicatechin in a mouse model of triple-negative mammary gland cancer using 4T1 breast cancer cells in female BALB/c mice. The researchers reported that (-)-epicatechin reduced tumor growth, with 2 and 3 mg/kg/day doses showing effects comparable to doxorubicin in this model. The study also found improved survival in (-)-epicatechin-treated animals compared with controls. Mechanistically, the authors reported changes in AMPK phosphorylation, Akt phosphorylation, and mTOR expression, suggesting that (-)-epicatechin may influence pathways involved in tumor-cell proliferation.
What this means in real life: This paper is relevant because it examines (-)-epicatechin in an animal model of an aggressive breast cancer subtype, while also looking at signaling pathways tied to cell growth and metabolism. The results are preclinical and should not be interpreted as evidence that (-)-epicatechin treats, prevents, or slows breast cancer in humans. The practical takeaway is narrower: this study adds to early mechanistic research on how (-)-epicatechin may affect tumor biology in controlled experimental models.
Clinical Relevance: Mouse triple-negative mammary gland cancer model, tumor growth and survival endpoints, AMPK and Akt/mTOR signaling; not human clinical evidence.
Related Content:
- Want to understand why cellular energy matters after cancer treatment? → Mitochondrial Health in Cancer Recovery: Why Cellular Energy Matters After Treatment
- Curious how cancer biology connects to mitochondria and energy regulation? → Cancer, Cellular Energy, and Mitochondria: Understanding the Biology Beneath the Surface
- Looking for another epicatechin oncology cell study? → Epicatechin and Breast Cancer Cell Migration in Vitro